Foa R, Meloni G, Guarini A, Mandelli F, Gavosto F
Dipartimento di Scienze Biomediche ed Oncologia Umana, Torino, Italy.
Leukemia. 1992 Nov;6 Suppl 4:92-4.
Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute leukemia patients. Here we shall discuss the biological and clinical observations which indicate that this innovative therapeutic approach may play a role in the management of minimal residual disease.
基于临床前研究结果以及最近更多的体内初步数据，有人提出白细胞介素2（IL2）免疫疗法可用于治疗急性白血病患者。在此，我们将讨论生物学和临床观察结果，这些结果表明这种创新的治疗方法可能在微小残留病的管理中发挥作用。
